DK3288946T3 - 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder - Google Patents

5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3288946T3
DK3288946T3 DK16721320T DK16721320T DK3288946T3 DK 3288946 T3 DK3288946 T3 DK 3288946T3 DK 16721320 T DK16721320 T DK 16721320T DK 16721320 T DK16721320 T DK 16721320T DK 3288946 T3 DK3288946 T3 DK 3288946T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
application
receptor agonists
ht2c receptor
Prior art date
Application number
DK16721320T
Other languages
Danish (da)
English (en)
Inventor
Albert S Ren
Xiuwen Zhu
Carleton R Sage
Graeme Semple
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of DK3288946T3 publication Critical patent/DK3288946T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16721320T 2015-04-27 2016-04-26 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder DK3288946T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153082P 2015-04-27 2015-04-27
PCT/US2016/029308 WO2016176177A1 (en) 2015-04-27 2016-04-26 5-ht2c receptor agonists and compositions and methods of use

Publications (1)

Publication Number Publication Date
DK3288946T3 true DK3288946T3 (da) 2019-11-25

Family

ID=55949111

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16721320T DK3288946T3 (da) 2015-04-27 2016-04-26 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder

Country Status (18)

Country Link
US (1) US10392390B2 (OSRAM)
EP (1) EP3288946B1 (OSRAM)
JP (1) JP6675688B2 (OSRAM)
KR (1) KR102275505B1 (OSRAM)
CN (1) CN107873030B (OSRAM)
AU (1) AU2016255009B2 (OSRAM)
BR (1) BR112017023088B1 (OSRAM)
CA (1) CA3002544C (OSRAM)
DK (1) DK3288946T3 (OSRAM)
EA (1) EA034446B1 (OSRAM)
ES (1) ES2757922T3 (OSRAM)
HK (1) HK1244005B (OSRAM)
HR (1) HRP20192044T1 (OSRAM)
HU (1) HUE047169T2 (OSRAM)
IL (1) IL255171A0 (OSRAM)
MX (2) MX373319B (OSRAM)
PT (1) PT3288946T (OSRAM)
WO (1) WO2016176177A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
PT3746126T (pt) 2018-01-30 2024-10-21 Apnimed Inc Delaware Métodos e composições para o tratamento de apneia do sono ou roncopatia simples
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
PH12021551850A1 (en) * 2019-02-08 2022-05-11 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
JP2022529353A (ja) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
US12205686B2 (en) * 2020-02-27 2025-01-21 The Cleveland Clinic Foundation Identifying patients for intensive hyperglycemia management
US20250073206A1 (en) * 2021-10-29 2025-03-06 Sensorium Therapeutics, Inc. Solid forms of mesembrine and therapeutic uses thereof
CA3240561A1 (en) * 2021-12-10 2023-06-15 GATC Health Corp Methods of treating addiction and neurological disorders
EP4489761A1 (en) 2022-03-10 2025-01-15 Arena Pharmaceuticals, Inc. Methods of treatment
CN114965250B (zh) * 2022-05-19 2025-02-14 道生天合材料科技(上海)股份有限公司 胶粘剂储存期的预测方法
WO2023225773A1 (en) * 2022-05-23 2023-11-30 Sensorium Therapeutics, Inc. Solid forms of mesembrine and therapeutic uses thereof
JP2025540125A (ja) * 2022-12-02 2025-12-11 アリーナ ファーマシューティカルズ,インコーポレイテッド 治療の方法
EP4665319A1 (en) * 2023-02-17 2025-12-24 Caamtech, Inc. 2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride
WO2024182807A2 (en) * 2023-03-02 2024-09-06 Alexander Shulgin Research Institute, Inc. Phenylalkylamine prodrugs
WO2025080932A1 (en) * 2023-10-11 2025-04-17 University Of Padova Methods of treatment with psilocybin and psilocin derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642822A (en) * 1969-11-03 1972-02-15 Upjohn Co Hexahydropyrrolobenzodiazepines
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
ES2230382T3 (es) * 2000-11-03 2005-05-01 Wyeth Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c.
WO2002036596A2 (en) 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
JP4782003B2 (ja) * 2003-06-17 2011-09-28 アリーナ ファーマシューティカルズ, インコーポレイテッド 5ht2cレセプター関連疾患の処置に有用なベンズアゼピン誘導体
TW200806321A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2013133325A1 (ja) * 2012-03-06 2013-09-12 武田薬品工業株式会社 三環性化合物
HK1212684A1 (zh) * 2012-09-14 2016-06-17 AbbVie Deutschland GmbH & Co. KG 三環喹啉和喹喔啉衍生物
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
HRP20192044T1 (hr) 2020-02-07
MX2017013902A (es) 2018-03-16
CN107873030B (zh) 2021-03-19
BR112017023088A2 (pt) 2018-07-10
CA3002544C (en) 2024-03-05
HUE047169T2 (hu) 2020-04-28
MX2020005898A (es) 2020-08-13
EA201792356A1 (ru) 2018-05-31
WO2016176177A1 (en) 2016-11-03
CN107873030A (zh) 2018-04-03
IL255171A0 (en) 2017-12-31
JP6675688B2 (ja) 2020-04-01
MX373319B (es) 2020-06-13
CA3002544A1 (en) 2016-11-03
NZ737412A (en) 2021-06-25
EP3288946B1 (en) 2019-08-21
KR20170140317A (ko) 2017-12-20
KR102275505B1 (ko) 2021-07-08
US20180186797A1 (en) 2018-07-05
PT3288946T (pt) 2019-11-27
EA034446B1 (ru) 2020-02-10
AU2016255009A1 (en) 2017-12-14
HK1244005B (en) 2020-04-17
EP3288946A1 (en) 2018-03-07
JP2018519251A (ja) 2018-07-19
US10392390B2 (en) 2019-08-27
AU2016255009B2 (en) 2020-10-08
BR112017023088B1 (pt) 2023-10-03
ES2757922T3 (es) 2020-04-30

Similar Documents

Publication Publication Date Title
DK3288946T3 (da) 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder
DK3350165T3 (da) Farnesoid-X-receptoragonister og anvendelser deraf
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3596053T3 (da) Farnesoid-x-receptoragonister og anvendelser deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3609888T3 (da) Farnesoid x-receptor-agonister og anvendelser deraf
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
EP3373906A4 (en) COMPOSITIONS AND METHOD OF APPLICATION TO THE SKIN
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
LT3419625T (lt) Fxr agonistų panaudojimo būdai
DK3653221T5 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3316909T5 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
KR20180084891A (ko) 구조 조성물 및 방법
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
IL257107A (en) 5-H-T2CC receptor agonists and preparations and methods of use
DK3227310T3 (da) Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
IL264682B (en) 5-HT2C receptor agonists and preparations and methods of use
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
IL272851A (en) Methods of using dipivefrin
DK3551617T3 (da) Sammensætninger og fremgangsmåder relateret til pyridinodylpiperidin-5-HT1F-agonister
DK3398598T3 (da) Sulfonamidderivat og fremstillingsmetode og anvendelse deraf